Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
6.48
+0.05 (0.78%)
At close: Jun 12, 2026, 4:00 PM EDT
6.33
-0.15 (-2.31%)
Pre-market: Jun 15, 2026, 5:55 AM EDT
Sagimet Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
400.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 2.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Autolus Therapeutics | 92.62M |
| Editas Medicine | 38.69M |
| vTv Therapeutics | 36.84M |
| Adlai Nortye | 5.00M |
| Ocugen | 4.47M |
| Artiva Biotherapeutics | 251.00K |
SGMT News
- 19 days ago - Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH - GlobeNewsWire
- 26 days ago - Sagimet Biosciences Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 27 days ago - Sagimet Biosciences price target lowered to $12 from $35 at Citizens - TheFly
- 4 weeks ago - Sagimet Biosciences price target lowered to $28 from $37 at Clear Street - TheFly
- 4 weeks ago - Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - GlobeNewsWire
- 4 weeks ago - Sagimet Biosciences reports Q1 EPS (33c), consensus (35c) - TheFly
- 4 weeks ago - Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 weeks ago - Sagimet Biosciences Quarterly report: Q1 2026 - Filings